open access

Vol 65, No 3 (2015)
Case report
Published online: 2015-06-18
Get Citation

Metastatic cancer of the bladder to the penis — a report of three cases and a literature review

Bogumiła Szyszka-Charewicz, Jadwiga Nowak-Sadzikowska, Tomasz Skóra, Mariusz Pietrasz, Jacek Ciupis, Jerzy Jakubowicz
DOI: 10.5603/NJO.2015.0045
·
Nowotwory. Journal of Oncology 2015;65(3):221-224.

open access

Vol 65, No 3 (2015)
Case report
Published online: 2015-06-18

Abstract

Over the course of nine years three patients with penile metastasis seeding from a primary bladder cancer were treated at our centre. Penile metastatic disease is generally thought of as a poor prognostic indicator and most patients die within a year of their diagnosis. Survival of our patients following diagnosis ranged from six to sixteen months which is comparable to the average described in the literature. In two of our patients, penile metastasis was the first sign of cancer spread and importantly they were largely asymptomatic until this time. This should prompt clinicians to consider penile metastasis in their review of bladder patients. Patients should also be made aware of the various presenting symptoms. Early recognition of a penile metastasis would lead to the faster implementation of treatments thereby improving a patient’s quality of life. As metastasis to the penis has a low incidence a causal understanding and defined palliative treatments remain uncertain in this group of patients. Depending on the type and severity of the primary tumour, symptoms secondary to the lesions and the patient’s general condition, surgical removal of the lesion by total or partial resection of the penis, and possible ureterostomia, palliative radiotherapy and chemotherapy all remain treatment options to be considered. In cases of severe pain difficult to control by other means, the dorsal penile nerve may be removed.

Abstract

Over the course of nine years three patients with penile metastasis seeding from a primary bladder cancer were treated at our centre. Penile metastatic disease is generally thought of as a poor prognostic indicator and most patients die within a year of their diagnosis. Survival of our patients following diagnosis ranged from six to sixteen months which is comparable to the average described in the literature. In two of our patients, penile metastasis was the first sign of cancer spread and importantly they were largely asymptomatic until this time. This should prompt clinicians to consider penile metastasis in their review of bladder patients. Patients should also be made aware of the various presenting symptoms. Early recognition of a penile metastasis would lead to the faster implementation of treatments thereby improving a patient’s quality of life. As metastasis to the penis has a low incidence a causal understanding and defined palliative treatments remain uncertain in this group of patients. Depending on the type and severity of the primary tumour, symptoms secondary to the lesions and the patient’s general condition, surgical removal of the lesion by total or partial resection of the penis, and possible ureterostomia, palliative radiotherapy and chemotherapy all remain treatment options to be considered. In cases of severe pain difficult to control by other means, the dorsal penile nerve may be removed.

Get Citation
About this article
Title

Metastatic cancer of the bladder to the penis — a report of three cases and a literature review

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 3 (2015)

Article type

Case report

Pages

221-224

Published online

2015-06-18

Page views

840

Article views/downloads

4567

DOI

10.5603/NJO.2015.0045

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(3):221-224.

Authors

Bogumiła Szyszka-Charewicz
Jadwiga Nowak-Sadzikowska
Tomasz Skóra
Mariusz Pietrasz
Jacek Ciupis
Jerzy Jakubowicz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl